Navigation Links
FDA Advisers Divided on Whether to Ban Diet Drug Meridia
Date:9/16/2010

red mixed reactions from experts.

According to the authors of the trial, which was funded by Meridia's maker, Abbott, the findings were generally in line with what has been known about the drug and shouldn't change how it is used.

"The only time you've got an increase in heart attacks or strokes were in those patients who had had previous heart disease or strokes, in other words, the people who . . . should never have received the drug in the first place," said Dr. Philip T. James, a professor at the London School of Hygiene and Tropical Medicine in England, and first author on the paper, which was published in the Sept. 2 issue of the New England Journal of Medicine.

Since January, Meridia (sibutramine) has carried a label warning that it should not be used by people with preexisting heart disease, so "the current prescription is entirely appropriate," James said.

However, not everyone agreed.

According to Dr. Greg Curfman, executive editor of the NEJM and co-author of an accompanying editorial, the FDA's January warning was based on preliminary information only. The new study results represented the first hard data, "the first outcomes trial," he said.

Based on the findings, he and others wondered if the drug was worth keeping around.

The drug did not seem to make people healthier, Curfman said. "Some people were actually made worse," he said. "All this taken together results in an unfavorable risk-benefit profile and, based on that, we don't see a rationale for keeping this on the market."

Also, he said, "the efficacy of producing weight loss with the drug is very unimpressive. In this trial, patients lost on average less than 4 kilograms [about 9 pounds] and we know that that's not going to translate into a real health benefit over time. It's not enough weight loss. The FDA has a benchmark of about 5 percent loss of baseline body weight to consider a weight-loss drug [effective]."

Anothe
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
2. FDA to Broaden Disclosure on Advisers Conflicts of Interest
3. FDA Advisers Urge Stricter Regulation of Tanning Beds
4. Experts Divided on Whether to Treat Thyroid Cancer
5. Surgeons impact whether a woman gets breast reconstruction, U-M study finds
6. Bond With Dad May Play Role in Whether Men Stress Out
7. Too Soon to Tell Whether Dengue Fever Will Spread in U.S.
8. After Violent Death, Bereaved Should Decide Whether to View Body
9. Clinical trial to test whether vaccine can effectively treat melanoma
10. Linwood Group Reveal Whether There is a Link Between Alcohol and Depression
11. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Divided on Whether to Ban Diet Drug Meridia
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... central role in regulating appetite and whole-body metabolism. A ... control of food intake and body weight, but the ... unclear. A new study in the ... in a type of neuron known as pro-opiomelanocortin (POMC) ... diet. Sabrina Diano and colleagues at Yale University ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... CLEVELAND, Ohio In a first-of-its-kind study, researchers at ... found that lap infants may be at greater risk ... analyzed pediatric medical emergencies on flights worldwide between January ... deaths occurred in children under the age of 2. ... MedAire to characterize the rare event of an in-flight ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
... "Thomson Reuters Citation Laureates" Recognized for Their,Contributions to ... Oct. 1 The Scientific business,of Thomson Reuters ... researchers likely to be in contention for Nobel ... winners to be announced in October., Each ...
... of serious public health issue through first ... Sudden cardiac arrest (SCA) claims,more lives each year ... a new Heart Rhythm Society survey, four out of ... health issue that causes,more than 250,000 deaths each year. ...
... developed a method of using nanoparticles to deliver treatments ... team led by Richard Borgens of the School of ... of Biomedical Engineering coated silica nanoparticles with a polymer ... That research is being published in the October edition ...
... Recession Fears - List Reports Aggregate Revenue of $185 Billion; Nuclear ... 100 Health Companies and No. 1161 on the Inc. 5000 With ... ... (PRWEB) October 1, 2008 -- Inc. today ranked www.mobilenuclear.com [Nuclear Medicine ...
... Ticker Symbol: CUR, QUEBEC CITY, Oct. 1 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... CEO of the Company, will be presenting a ... Focus Conference on,Monday, October 6, 2008, at 1:30 ...
... with No Monthly ... Premium, ... serving seniors and others with Medicare,announced today that its new Medicare Advantage ... with no monthly plan premiums and no deductibles., "Access to affordable, ...
Cached Medicine News:Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 2Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 3Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 4Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 5Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 2Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 3Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 4Health News:Researchers use nanoparticles to deliver treatment for brain, spinal cord injuries 2Health News:America's 5000 Fastest-Growing Private Companies Revealed 2Health News:DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008 2Health News:SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 2
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Contaminated with Diethylene Glycol,(DEG) Remains a Potential ... Md., May 4, 2007-The U.S. Food and ... repackers, and health professionals who compound,medications to ... a,sweetener commonly used worldwide in liquid over-the-counter ...
... ROCKVILLE, Md., April 25, 2007-The U.S. Food ... a Consent Decree of,Permanent Injunction against PharmaFab ... officials, Mark Tengler, PharmaFab's president,and Russ McMahen, ... the illegal manufacture and distribution of prescription ...
Cached Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2Major Manufacturer of Unapproved and Adulterated Drugs 2Major Manufacturer of Unapproved and Adulterated Drugs 3
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
FLEXILOG spare part....
FLEXILOG spare part....
Complete calibration kits are available for both pH and manometry systems....
Medicine Products: